GeneDx Holdings Corp.
NASDAQ:WGS · NASDAQ Global Market
+$1.52 today
Vol 0.66M · Avg 1.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-6.8%
avg -840.7%
ROIC
-2.5%
avg -62.6%
ROA
-3.7%
avg -42.7%
Analysis
ROIC is currently the strongest return metric at -2.5% versus its period average of -62.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Katherine A. Stueland | President, Chief Executive Officer & Director | $1.81M | — | 50 | $99,762.00 | 0.34% |
Kevin Feeley | Chief Financial Officer | $932,000.00 | — | 45 | $4,925.00 | 0.02% |
Bryan Dechairo | Chief Operating Officer | $882,404.00 | — | 53 | $10,430.00 | 0.04% |
Martin G. Reese | President of Fabric Genomics | — | — | — | — | — |
Jami Biliboaca | Chief People Officer | — | — | — | — | — |
Linda Genen | Chief Medical Officer | — | — | — | — | — |
Lisa Gurry | Chief Business Officer | — | — | — | — | — |
Melanie Duquette | Chief Growth Officer | — | — | — | — | — |
Sabrina Dunbar | Director of Investor Relations & Communications | — | — | — | — | — |
Heidi C. Chen | Chief Legal Officer | — | — | 59 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
37
$106.60M
Sells
103
$22.58M
Net Sentiment
+$84.02M
Net buying
Most Active
Stueland Katherine
38 transactions
1–10 of 140
Analysis
Insiders reported 37 buys worth $106.60M and 103 sells worth $22.58M over the last 12 months. That adds up to net buying of $84.02M. Stueland Katherine was the most active insider with 38 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +4.1% | +28.3% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +4.1% over three years. Forward estimates point to Revenue at +28.3% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.43B
Oscar Health, Inc.
NYSE:OSCR
$7.30B
Immunovant, Inc.
NASDAQ:IMVT
$7.11B
Hinge Health, Inc.
NYSE:HNGE
$5.25B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.74B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.53B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.48B
Option Care Health, Inc.
NASDAQ:OPCH
$3.47B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.97B
TransMedics Group, Inc.
NASDAQ:TMDX
$2.74B
Who manages WGS?
GeneDx Holdings Corp. (WGS) lists 10 active executives. The top listed executive is Bryan Dechairo, Chief Operating Officer.
Are WGS insiders buying or selling?
Recent insider activity shows net buying of $84.50M.
Explore More
Continue the stock analysis
Jump to another research area for this company.